First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer (NCT07756281) | Clinical Trial Compass
Not Yet RecruitingPhase 1
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
40 participantsStarted 2026-09
Plain-language summary
This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults (18 years and older).
* Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
* Cancer confirmed by tissue or cell examination (histology or cytology).
* At least one measurable tumor on scans.
* Good enough general health and organ function to receive study treatment, as judged by the study doctor.
* Able to swallow oral medicines.
* Willing to follow study visit schedule and contraception requirements.
Exclusion Criteria:
* Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.
* Active, uncontrolled infections.
* Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).
* Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).
* Known brain or nervous system involvement from the cancer that is not stable or controlled.
* Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities
Timeframe: through study completion, an average of 1 year